The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic
autoimmune diseases that affect the skeletal muscles and can also involve the skin, joints …

The use of immune checkpoint inhibitors (ICIs) has represented a major advance in cancer
treatment. By enhancing endogenous immune responses to destroy cancer cells, ICIs can …

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …

While the spectrum of neurological immune checkpoint inhibitor-related adverse events is
expanding, patients' outcomes are not well documented. This study aimed to assess …

Background Neurological immune-related adverse events (irAE-n) are severe and
potentially fatal toxicities of immune checkpoint inhibitors (ICI). To date, the clinical …

Idiopathic inflammatory myopathies (IIMs) are severe autoimmune diseases with poorly
understood pathogenesis and unmet medical needs. Here, we examine the role of interferon …

Immune checkpoint inhibitors, a class of oncological treatments that enhance antitumour
immunity, can trigger neurological adverse events closely resembling paraneoplastic …

In recent years, a wide range of cancer immunotherapies have been developed and have
become increasingly important in cancer treatment across multiple oncologic diseases. In …

Objectives Inflammatory myopathy or myositis is a heterogeneous family of immune-
mediated diseases including dermatomyositis (DM), antisynthetase syndrome (AS), immune …

As the use of cancer immunotherapy with immune checkpoint inhibitors (ICIs) is expanding
rapidly for the treatment of many tumor types, it is crucial that both neurologists and …